Trial Outcomes & Findings for Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive (NCT NCT02982018)
NCT ID: NCT02982018
Last Updated: 2018-07-19
Results Overview
Eyestrain related to glare was assessed at the 2-, 4-, 8- and 12- week follow-up visits using an 11-item questionnaire. This questionnaire assesses patient-experience attributes of soft contact lenses. Derived eyestrain related to glare scores using Item Response Theory (IRT) follow a normal distribution with a mean of 50 and a standard deviation of 10. Scores in this study ranged from 30 to 70. Lower scores indicate better performance. This questionnaire is still under development and the data collected is considered exploratory.
COMPLETED
NA
133 participants
Up to 12-Week Follow-up
2018-07-19
Participant Flow
A total of 133 subjects were enrolled into the study. Of the enrolled subjects 131 were dispensed study lenses and 2 subjects failed to meet the eligibility criteria. Of the dispensed subjects 123 completed the study and 8 subjects were discontinued.
Participant milestones
| Measure |
Senofilcon A With New UV Blocker
Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.
|
Senofilcon A
Subjects that wore the senofilcon A lens throughout the entire duration of the study.
|
|---|---|---|
|
Overall Study
STARTED
|
67
|
64
|
|
Overall Study
COMPLETED
|
62
|
61
|
|
Overall Study
NOT COMPLETED
|
5
|
3
|
Reasons for withdrawal
| Measure |
Senofilcon A With New UV Blocker
Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.
|
Senofilcon A
Subjects that wore the senofilcon A lens throughout the entire duration of the study.
|
|---|---|---|
|
Overall Study
Incorrect Lens Dispensed
|
1
|
0
|
|
Overall Study
Protocol Violation
|
1
|
1
|
|
Overall Study
Adverse Event
|
1
|
1
|
|
Overall Study
Lens Discomfort
|
2
|
0
|
|
Overall Study
Withdrawal by Subject
|
0
|
1
|
Baseline Characteristics
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Baseline characteristics by cohort
| Measure |
Senofilcon A With New UV Blocker
n=67 Participants
Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.
|
Senofilcon A
n=64 Participants
Subjects that wore the senofilcon A lens throughout the entire duration of the study.
|
Total
n=131 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
31.2 Years
STANDARD_DEVIATION 8.15 • n=99 Participants
|
32.1 Years
STANDARD_DEVIATION 7.99 • n=107 Participants
|
31.6 Years
STANDARD_DEVIATION 8.02 • n=206 Participants
|
|
Sex: Female, Male
Female
|
45 Participants
n=99 Participants
|
47 Participants
n=107 Participants
|
92 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
22 Participants
n=99 Participants
|
17 Participants
n=107 Participants
|
39 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian
|
6 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
4 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
White
|
56 Participants
n=99 Participants
|
62 Participants
n=107 Participants
|
118 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Other
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Up to 12-Week Follow-upPopulation: Subjects that completed all study visits without a major protocol deviation.
Eyestrain related to glare was assessed at the 2-, 4-, 8- and 12- week follow-up visits using an 11-item questionnaire. This questionnaire assesses patient-experience attributes of soft contact lenses. Derived eyestrain related to glare scores using Item Response Theory (IRT) follow a normal distribution with a mean of 50 and a standard deviation of 10. Scores in this study ranged from 30 to 70. Lower scores indicate better performance. This questionnaire is still under development and the data collected is considered exploratory.
Outcome measures
| Measure |
Senofilcon A With New UV Blocker (Test)
n=61 Participants
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
|
Senofilcon A (Control)
n=59 Participants
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
|
|---|---|---|
|
Eyestrain Related to Glare
2-Week Follow-up
|
44.64 Units on a Scale
Standard Deviation 6.562
|
45.37 Units on a Scale
Standard Deviation 7.631
|
|
Eyestrain Related to Glare
4-Week Follow-up
|
46.40 Units on a Scale
Standard Deviation 7.489
|
44.59 Units on a Scale
Standard Deviation 7.300
|
|
Eyestrain Related to Glare
8-Week Follow-up
|
44.67 Units on a Scale
Standard Deviation 6.751
|
43.57 Units on a Scale
Standard Deviation 6.012
|
|
Eyestrain Related to Glare
12-Week Follow-up
|
43.66 Units on a Scale
Standard Deviation 5.921
|
44.02 Units on a Scale
Standard Deviation 7.687
|
PRIMARY outcome
Timeframe: Up to 12-Week Follow-upPopulation: Subjects that completed all study visits without a major protocol deviation.
Distance logMAR Visual Acuity was assessed for each subject and eye at 2-, 4- 8- and 12-weeks. The average logMAR visual acuity for each lens and time point was reported. Lower values of logMAR indicate better vision.
Outcome measures
| Measure |
Senofilcon A With New UV Blocker (Test)
n=122 Eyes
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
|
Senofilcon A (Control)
n=118 Eyes
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
|
|---|---|---|
|
Distance Monocular logMAR Visual Acuity (VA)
2-Week Follow-up
|
-0.107 logMAR
Standard Deviation 0.0673
|
-0.080 logMAR
Standard Deviation 0.0663
|
|
Distance Monocular logMAR Visual Acuity (VA)
4-Week Follow-up
|
-0.106 logMAR
Standard Deviation 0.0713
|
-0.091 logMAR
Standard Deviation 0.0678
|
|
Distance Monocular logMAR Visual Acuity (VA)
8-Week Follow-up
|
-0.115 logMAR
Standard Deviation 0.0776
|
-0.0881 logMAR
Standard Deviation 0.0665
|
|
Distance Monocular logMAR Visual Acuity (VA)
12-Week Follow-up
|
-0.105 logMAR
Standard Deviation 0.0769
|
-0.0892 logMAR
Standard Deviation 0.0686
|
PRIMARY outcome
Timeframe: Up to 12-Week Follow-upPopulation: All subjects that were dispensed at least one study lens.
Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 2-4-8- and 12-week follow-ups. A new response variable was derived by dichotomizing the data as follows: 1 if a Grade 3or higher SLF was observed and 0 otherwise. The Percentage of eyes with Grade 3 or higher SLFs was reported for each lens and time point.
Outcome measures
| Measure |
Senofilcon A With New UV Blocker (Test)
n=134 Eyes
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
|
Senofilcon A (Control)
n=128 Eyes
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
|
|---|---|---|
|
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
2-Week Follow-up
|
0 Percentage of eyes
|
0 Percentage of eyes
|
|
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
4-Week Follow-up
|
0 Percentage of eyes
|
0 Percentage of eyes
|
|
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
8-Week Follow-up
|
0 Percentage of eyes
|
0 Percentage of eyes
|
|
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
12-Week Follow-up
|
0 Percentage of eyes
|
0 Percentage of eyes
|
SECONDARY outcome
Timeframe: Up to 12-Week Follow-upPopulation: Subjects that completed all study visits without a major protocol deviation.
Contact lens wearing time (hours) was self-reported by each subject at the 2-, 4-, 8- and 12-week follow-ups. The average contact lens wearing time (hours) for each lens and time point was reported.
Outcome measures
| Measure |
Senofilcon A With New UV Blocker (Test)
n=61 Participants
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
|
Senofilcon A (Control)
n=59 Participants
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
|
|---|---|---|
|
Contact Lens Wearing Time
2-Week Follow-up
|
14.7 Hours
Standard Deviation 1.76
|
14.0 Hours
Standard Deviation 2.14
|
|
Contact Lens Wearing Time
4-Week Follow-up
|
14.5 Hours
Standard Deviation 2.03
|
14.2 Hours
Standard Deviation 2.14
|
|
Contact Lens Wearing Time
8-Week Follow-up
|
14.6 Hours
Standard Deviation 1.78
|
14.1 Hours
Standard Deviation 2.02
|
|
Contact Lens Wearing Time
12-Week Follow-up
|
14.7 Hours
Standard Deviation 1.67
|
14.3 Hours
Standard Deviation 1.83
|
SECONDARY outcome
Timeframe: Up to 12-Week Follow-upPopulation: All subjects that were dispensed at least one study lens.
Symptoms, problems and complaints are subject reported and were collected for each subject eye at the 1-, 2-, 4-, 8- and 12-week follow-up evaluations. The data is reported as a binary outcome of yes if a subject experience a problem or complaint or no otherwise. Symptoms, problems and complaints include the following: Burning/Stinging, Itchiness/Scratchiness, Dryness, Lens Awareness, Grittiness/Foreign Body Sensation, Redness, Irritation/Discomfort, Cloudy/Blurry/Hazy, Variable Vision and Other The Percentage of subjects eyes with symptoms, problems or complaints was reported for each lens and time point.
Outcome measures
| Measure |
Senofilcon A With New UV Blocker (Test)
n=134 Eyes
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
|
Senofilcon A (Control)
n=128 Eyes
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
|
|---|---|---|
|
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
2-Week Follow-up
|
15.2 Percentage of eyes
|
23.3 Percentage of eyes
|
|
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
1-Week Follow-up
|
12.9 Percentage of eyes
|
13.3 Percentage of eyes
|
|
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
4-Week Follow-up
|
14.1 Percentage of eyes
|
11.3 Percentage of eyes
|
|
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
8-Week Follow-up
|
14.1 Percentage of eyes
|
16.9 Percentage of eyes
|
|
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
12-Week Follow-up
|
12.7 Percentage of eyes
|
10.7 Percentage of eyes
|
Adverse Events
Senofilcon A With New UV Blocker
Senofilcon A
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
John Buch- SENIOR PRINCIPAL RESEARCH OPTOMETRIST
Johnson & Johnson Vision
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60